Youthono Bio Completes RMB 150 Million Series A+ Financing to Advance Allogeneic CAR-T Therapies

Recently, UCELLO completed an A+ round of financing worth 150 million RMB. This round was led by Shenzhen Juke Investment Co., Ltd., with participation from Guozhong Capital and Penglai Capital. Existing shareholders Chengdu Biocity Equity Investment Fund Management Co., Ltd., Matrix Partners China, and CoWin Ventures also increased their investments. The funds raised from this round will be used to accelerate the industrialization of the company’s allogeneic universal CAR-T cell therapy products and advance the new drug application and market launch process. UCELLO is a biotechnology startup focused on the development and commercialization of universal cell therapy products. It was established in December 2020 at the Chengdu Tianfu International Bio City. Based on its proprietary and continuously optimized universal CAR-T cell technology platform CBT-X20, UCELLO has developed multiple "off-the-shelf" cell therapy products targeting malignant tumors.